EP Patent

EP3390395B1 — Compounds useful as kinase inhibitors

Assigned to Loxo Oncology Inc · Expires 2020-09-09 · 6y expired

What this patent protects

Patent listed against null.

Drugs covered by this patent

Patent Metadata

Patent number: EP3390395B1
Jurisdiction: EP
Classification: —
Expires: 2020-09-09
Drug substance claim: No
Drug product claim: No
Assignee: Loxo Oncology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.